OOIR: Observatory of International Research

Papers

(The H4-Index of npj Precision Oncology is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	289
Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers	140
Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies	127
The dynamic immune behavior of primary and metastatic ovarian carcinoma	116
Mucin-1: a promising pan-cancer therapeutic target	113
KMT2C inactivation leads to PTEN downregulation and tolerance to DNA damage during cell cycle progression	113
MYSM1 promotes lung adenocarcinoma progression via TRAF2/3-mediated activation of MAPK and non-canonical NF-κB pathways	111
Sub-regional radiomics combining multichannel 2-dimensional or 3-dimensional deep learning for predicting neoadjuvant chemo-immunotherapy response in esophageal squamous cell carcinoma: a multicenter	105
Exosome- transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA/Hippo axis	105
Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning	86
Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment	70
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes	66
Development and testing of a polygenic risk score for breast cancer aggressiveness	62
Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants	62
A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3	59
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	58
Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood	58
Author Correction: An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	56
Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study	55
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP	55
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	55
Patient-level proteomic network prediction by explainable artificial intelligence	53
Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI)	52
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1	51
Interferon signaling and ferroptosis in tumor immunology and therapy	51

Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates	50
Barriers and opportunities in pancreatic cancer immunotherapy	50
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study	48
Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer	47
Erigoster B targeting DECR1 induces ferroptosis of breast cancer cells via promoting phosphatidylcholine/arachidonic acid metabolism	47
User-centered design approach to visualize PROMs for molecular tumor boards	46
Establishing predictive machine learning models for drug responses in patient derived cell culture	45
Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma	45
Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients	44
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma	44
ECM-based molecular subtypes define prognostic, EMT status, and therapeutic diversity in IDH-mutant gliomas	43
TRIM65 regulates glucose metabolic reprogramming to promote glioma cell proliferation via ubiquitination and degradation of AMPK	42
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy	42
Machine learning model for predicting tertiary lymphoid structures and treatment response in triple-negative breast cancer	42
Collagen disorder architecture features are associated with clinical, molecular, genetic factors and survival outcomes in colon cancer	42
First-in-human prospective trial of sonobiopsy in high-grade glioma patients using neuronavigation-guided focused ultrasound	41